NCI’s Role in Cancer Research
How Cancer Research Works
When people think about cancer research, they may envision men and women in lab coats, carefully dripping substances into test tubes or peering thoughtfully into microscopes. Of course, those things do happen in biomedical research. But they are just one small part of a much larger research landscape.
In reality, cancer research is a vast, complex enterprise that involves researchers from many different disciplines. It also relies heavily on the participation of patients and healthy volunteers, without whom cancer research would not be possible.
Cancer research happens in many places, such as:
- the lab, with investigators studying the inner workings of cells
- hospitals, with doctors administering treatments to patients as part of clinical trials
- community clinics, with nurses or health educators teaching people how to reduce their cancer risk
- universities and academic medical centers across the country and the world, where doctors, professors, fellows, and students unravel the complexity of cancer
- the offices of NCI staff who analyze data to identify behaviors, exposures, or other factors that influence cancer risk or cancer outcomes
- NCI program offices, where staff review applications from researchers across the country who are hoping to secure funding for their research projects
Research Begins with Ideas
An idea. That’s the genesis of a cancer research study.
It could be an idea for a large-scale project like The Cancer Genome Atlas, a multiyear effort that involved researchers from institutions across the country working collaboratively to catalogue all of the changes to DNA and molecules in more than 30 different cancer types. Or it could be something more modest, such as testing whether a text messaging service can help pregnant women quit smoking.
Ideas for new cancer research studies are often inspired by findings from earlier research, research on other cancers, and even findings from research done on other diseases, such as diabetes or immune disorders.
Findings from basic research, such as studies of cancer cells in the laboratory, can ultimately define research questions to study in humans, such as helping to identify drugs to test in clinical trials. And findings from clinical trials in humans can, conversely, generate hypotheses that need to be further investigated in cells or animal models in the lab. An epidemiologic study can help identify potential risk factors for certain cancers and generate hypotheses about what may cause some cancers or suggest possible preventive measures.
It’s all part of a continuum of innovation and knowledge that produces important biomedical advances. Each advance builds on the next, and each advance spurs new ideas.
The Cancer Research Continuum
Although studies of new cancer treatments often receive the most headlines, cancer research involves much more than testing new therapies.
Learning more about how to treat and prevent cancer entails the work of researchers from a wide range of disciplines, many of whom will never handle a frozen tissue sample or don a white lab coat or hospital scrubs.
Generally, biomedical research falls into four categories, each of which is essential to advances in cancer research overall.
Why do cancer cells grow and spread uncontrollably? What causes a cell to become cancerous in the first place?
To answer basic research questions like these, investigators study bacteria, viruses, fungi, animal cells and human cells (both healthy and cancerous) grown in the lab, and tumors in animals, such as mice and rats.
Basic research increases our knowledge and understanding of nature and its laws. This type of research can be driven by curiosity, often without regard to practical applications. However, basic research is the foundation for solving many practical and important problems. It provides the raw materials for tomorrow’s scientific and technical advances.Some examples of basic research in cancer biology might include:
- defining the communication pathways in cells that regulate processes such as cell proliferation and the repair of damaged DNA
- analyzing how healthy cells respond to injury from a suspected cancer-causing toxin
- analyzing how cancer cells and malignant tumors growing in animals respond to an investigational drug
- detailing the physical structure of a protein receptor commonly found on the surface of cancer cells, which may aid in developing drugs that target the protein
- determining the biological differences between immune system cells that attack and kill cancer cells and those that ignore them
Basic research requires painstaking attention to detail and often involves an iterative approach, meaning that individual projects can often span periods of months or years. But without basic research, it would be impossible to develop new ways to prevent and treat cancer. Basic research is the foundation on which much of the cancer research continuum is built.
Nearly every new treatment, test, or intervention for cancer must be rigorously tested in clinical trials to be sure that it is safe and effective before it can be used routinely in humans.
In clinical trials, researchers test drugs, medical devices, or other interventions in human volunteers, with the goal of improving all aspects of patient care.
Trials are used to find answers to many different clinical questions, such as:
- Can a new (or old) drug prevent cancer in people at increased risk of the disease (such as those with certain genetic mutations or a family history of a specific cancer)?
- Does a new screening test reduce deaths from the cancer that it is meant to detect?
- Can taking a drug or making a lifestyle change (e.g., exercise, diet) after treatment extend the lives of patients with cancer?
- Which of two commonly used treatments for the same cancer is more effective or safer?
- Can a new drug or intervention improve patients’ quality of life?
Initial, or early-phase, clinical trials of a potential new therapy are very small, with just a handful of participants, and are conducted primarily to determine whether a new treatment is safe and to identify the best dose to test in larger trials.
Later-phase clinical trials, which often take several years or more to conduct, often involve hundreds or thousands of patients. These trials are used to determine whether a treatment is more effective and/or better tolerated than current treatments and should be used more broadly.
Increasingly, additional studies (often called correlative studies) are built into clinical trials. These additional studies are intended to help researchers better understand issues such as why some patients in the trial did or didn’t respond to a new treatment or how treatments affect patients’ quality of life.
Studying populations of people—their family histories and genetics, health behaviors and health histories, and environmental exposures—can provide important information about the causes of cancer and its consequences.
Are any risk factors (e.g., gene mutations, environmental exposures) common among people who develop a certain kind of cancer? After completing treatment for cancer, what was the state of the emotional and psychological well-being of the population studied? Often, these types of questions can only be answered by studying large groups of people.
Population studies can involve:
- mining data from cancer registries and databases (such as NCI’s SEER registry, one of the largest of its kind in the world)
- studies of large families in which the same cancer was diagnosed in multiple members or registries of families with hereditary cancers
- observational studies, including case-control and cohort studies
- comprehensive surveys of specific population groups
Population-based research can identify associations or highlight trends that would be difficult or impossible to find otherwise. Important data about disparities in diagnosis or survival rates among certain racial or socioeconomic groups or the long-term health of pediatric cancer survivors, for instance, only came to light as a result of population-based research.
The results of basic and clinical research or population studies don’t exist in a vacuum. Some form the basis for interventions—for example, a new treatment or a strategy for improving use of a proven therapy—that are tested to determine whether they can improve health outcomes.
And if those studies suggest that an intervention can improve health outcomes, additional research is often needed to assess how it’s being used outside of a controlled study like a clinical trial or to test ways to overcomes barriers to its use in everyday clinical practice.
This type of research is often called translational research. In the context of medicine, it is often called bench to bedside or bedside to practice (also called “implementation research”).
Because it is so broad, translational research often overlaps with the other areas of research. Clinical trials, for example, are considered by many researchers to be a critical component of translational research.
Regardless, the ultimate goal of translational research is to help ensure that findings from earlier studies with the potential to affect clinical care are tested and, if shown to be effective, are eventually incorporated into everyday care in the most effective and efficient means possible.
Research Is Often a Marathon, Not a Sprint
Although these different areas of research are distinct in many ways, they also have something in common: they are often performed over a period of years and, in some cases, decades.
To take a finding in basic research, such as identifying a mutant protein that drives a particular cancer, and develop a drug that inactivates the protein and performs well in cells in the lab and in animal models can take years, if not decades.
Even once a drug makes it to late-phase clinical trials, patients must be followed for several years, or even a decade or more, to determine whether the new treatment is more effective than current treatments. And, in population-based studies, researchers typically collect a substantial amount of data on the groups being studied and often follow them (via interviews, surveys, medical records, etc.) for many years.
Technology and Collaboration Fuel Progress
Cancer researchers are increasingly using advanced technologies that are capable of providing far more information and detail than was previously possible, propelling the shift toward precision medicine. Some of these technologies include:
- next-generation DNA sequencing and gene and protein array platforms, which allow researchers to perform more comprehensive molecular analyses of tumors, more quickly and accurately, than was possible with older technology
- advanced imaging technologies that allow researchers to obtain biopsy samples with more precision or measure the inner workings of cancer cells and their microenvironments
- new bioinformatics tools for storing and analyzing the large amounts of data captured in the course of much cancer research today
And cancer research now involves collaborative efforts from researchers in disciplines such as physics, advanced mathematics, structural biology, nanotechnology, and many more, who have introduced new concepts and approaches to studying cancer.
There is also greater collaboration among the chief funders of cancer research: the government, the private sector, and nonprofit organizations. This collaboration is allowing patients and advocates to become more involved in guiding and developing studies and allowing researchers to overcome issues related to intellectual property that can sometimes stall or halt important research projects.
NCI: The Largest Funder of Cancer Research
NCI is the largest funder of cancer research in the world. The institute’s annual budget, which is set by Congress, is approximately $5 billion. These funds support research performed at NCI and at cancer centers, hospitals, community clinics, and universities across the United States and around the world.
NCI has a number of divisions and centers that either conduct research or manage research programs.
The NCI intramural program is carried out by both government and contract staff, who conduct research at one of several campuses in suburban Maryland. Intramural research spans the research continuum.
The bulk of NCI’s budget supports the extramural program—the investigators and institutions across the country who use federal funds to conduct cancer research. The extramural program includes:
- independent investigators at universities and academic medical centers who work on basic and clinical research
- special programs focused on specific research areas, such as genomics and health disparities.
- the NCI-designated Cancer Centers program
- the National Clinical Trials Network and other research networks
In both the intramural and extramural programs, NCI conducts and supports research on rare cancers. This work is an important part of NCI’s mission and allows the institute to support research into cancers not typically of interest to the private sector. As a federal agency, NCI is able to study interventions and drugs that also might not be of interest to the private sector, for instance because they are no longer under patent protection or they are not anticipated to be profitable.
Supporting the Cancer Research Enterprise
NCI offers a number of important resources and services for cancer researchers.
NCI offers a variety of training programs for early-career and international investigators that span the research continuum. Training opportunities are available for high school students, graduate students, scientists, clinicians, and health care professionals. Some of these programs include training in:
- basic and translational science
- cancer prevention
- behavioral research
- regulatory science
These programs are run through NCI’s divisions and centers, some of which include partnerships with other HHS institutes and universities.
NCI Grants and Peer Review
In order to receive NCI funding, researchers submit proposals for research projects, outlining what the project will entail, the scientific rationale for the project, and what they hope to show. Proposals can be submitted without any solicitation, but some are submitted in response to research requests (RFAs, RFPs, PAs) developed by NCI staff.
These proposals are then subject to peer review, in which independent experts from outside NCI review and score the applications based on factors such as applicability to cancer, scientific merit, and feasibility, among others.
Because many cancer research studies produce vast amounts of data, cancer researchers are increasingly reliant on bioinformatics tools to conduct their work. Bioinformatics enables researchers to manage and analyze the very large data sets generated by clinical trials, genomics studies, and population-based research.
Led by the National Cancer Informatics Program, developing and managing bioinformatics resources—including web-based databases and “cloud computing” tools—has become a core component of the NCI’s research enterprise.
Several independent advisory boards guide decisions by NCI leadership, including funding support for proposed or ongoing research projects and programs.
These advisory boards, which include leading cancer researchers and cancer research advocates, meet regularly throughout the year to review the status and progress of NCI’s intramural and extramural programs. During these meetings, the advisory boards often recommend funding levels at which programs should be supported and changes to the composition and/or direction of different programs.
Divisions, Offices, Centers, and Special Programs
The program staff in NCI’s divisions, offices, and centers are highly experienced in their respective fields (e.g., cancer biology, prevention, clinical trials, etc.). NCI staff:
- prioritize and develop concepts for research programs
- evaluate research proposals submitted by extramural investigators
- work with investigators to manage their research grants
- conduct training programs for intramural and extramural researchers
- aid in NCI’s strategic planning and prioritization process
In addition to conducting and funding research to develop more effective and safer therapies, NCI has thriving research programs in critically important areas like survivorship, delivery of care, primary prevention, screening, and quality of life—areas that are not traditionally supported by the private sector because they have limited commercial value or are not a good fit with traditional pharmaceutical and biotech business models.
Funding for these areas of research is vital to making advances that cut across the spectrum of cancer care. Advances in symptom control, for example, can ensure people undergoing cancer treatment have an improved quality of life and, in many cases, save health care resources. Advances in delivery of care can improve the overall quality of treatment, improving patient outcomes and saving health care dollars.
Funding the Best Science
Like other components of the federal government, NCI must operate within the confines of its budget. Because medical inflation has outpaced general inflation and NCI has had a relatively flat budget over much of the last decade, the institute’s purchasing power has declined substantially.
NCI senior leadership has worked closely with its advisory boards to make difficult choices about funding, including whether to fund a project or program at all or adjust their funding levels. Decisions about funding are heavily influenced by the areas of research considered by NCI leadership and its advisory boards to be the highest priority and have the greatest potential to produce important advances and improve patients’ lives.